Experimental drug offered to patients with rare gut disorder
NCT ID NCT05232110
First seen Nov 10, 2025 · Last updated May 24, 2026 · Updated 28 times
Summary
This trial gives people with CD55-deficient protein-losing enteropathy access to an experimental drug called pozelimab. The condition causes the gut to leak proteins, leading to serious health problems. The goal is to control the disease and improve symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD55-DEFICIENT PROTEIN-LOSING ENTEROPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.